Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. Effects of regorafenib (REG) therapy on health-related quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback